Public Law (PL) 115-92

What is Public Law (PL) 115-92?

On December 12, 2017, the President signed into law Public Law No. 115-92 (P.L. 115-92), an Act to amend the Federal Food,
Drug, and Cosmetic Act (FD&C Act) to authorize additional emergency uses for medical products to reduce deaths and severity
of injuries caused by chemical, biological, radiological, or nuclear (CBRN) agents or agents that may cause, or are otherwise
associated with, an imminently life-threatening and specific risk to the U.S. military forces and for other purposes. P.L. 115-92
requires enhanced collaborations and communication between the U.S. Department of Defense (DoD) and the U.S. Food and Drug
Administration (FDA) on DoD's medical product priorities (MPPs) for military emergencies.

What are the features of PL 115-92?

P.L. 115-92 amended the FD&C Act to provide, among other things, specific policy for increased DoD-FDA collaboration on the
development and availability of MPPs. In summary, P.L. 115-92:

Expands FDA's emergency use authorization (EUA) authority under §564 of the FD&C Act to allow FDA to issue EUAs for
emergency use of unapproved medical products or unapproved uses of approved medical products to address additional types of
threats (beyond CBRN agents) related to attack with an "agent or agents that may cause, or are otherwise associated with,
an imminently life-threatening and specific risk to the United States military forces" (see §1(a), P.L. 115-92);

Allows the Secretary of Defense to request, and authorizes FDA to take, specific actions to expedite the development of
medical products, and the review of investigational submissions, applications for approval/licensure, and submissions/notifications
for clearance for such medical products reasonably likely to diagnose, prevent, treat, or mitigate a specific and life-threatening
risk to the U.S. military (see §1(b), P.L. 115-92); and

How will PL 115-92 be implemented?

USAMRDC and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have
been working with the office of the Deputy Assistant Secretary of Defense for Health Readiness Policy and Oversight (DASD(HRP&O))
to implement P.L. 115-92. The main features of this implementation are:

A Memorandum of Understanding (MOU) between DoD and FDA to implement the new collaboration was signed on November 2, 2018.
This MOU was negotiated by the Commissioner of Food and Drugs and the Principal Deputy Assistant Secretary of Defense for
Health Affairs (PDASD(HA)) with the assistance of our legal and regulatory teams.

The Medical Product Acceleration Committee (MPAC) has been informally established to manage the creation and maintenance of the
DoD Priority List of MPPs that will be communicated to FDA, via the Assistant Secretary of Defense for Health Affairs (ASD(HA)),
at the Semi-Annual and CBER Quarterly meetings required by the statute. The MPAC is intended to serve as the DoD enterprise-wide
forum for discussions on which products are identified as DoD MPPs for the Priority List. The MPAC aims to achieve a DoD "one voice"
approach envisioned by the statute.

What will be the impact on DoD Medical Product Development?

P.L. 115-92 has already significantly benefited DoD medical product development. The recent EUA for French Freeze Dried Plasma, the FDA
approval of tafenoquine for the prevention of severe malaria, and the approval the atropine autoinjector for the treatment of chemical
nerve agent poisoning, among other examples, are all fruits of this new collaboration. We expect this statute to expedite review and
approval of DoD medical products and enhance DoD-FDA collaboration. Future success will depend on (i) the level of coordination and
communication horizontally across the DoD enterprise, and (ii) the clarity with which DoD speaks with "one voice" to FDA.

For DoD Collaborators

In order to accomplish our product development mission, USAMRDC relies on our private collaborators to a large degree. For potential
collaborators interested in the potential benefits of PL 115-92 for your product idea, please review the helpful resources on this page.
Primarily, we look for submissions to our
New Product Ideas portal and encourage collaborators to read the helpful,
Doing Business with USAMRDC
manual, which provides an overview of how collaborations are formed and how business opportunities are communicated. In addition, companies
considering partnering with us may contact us for further information.

Please note that questions about DoD's process for creating the DoD Priority List, evaluating potential products useful to DoD or their
placement on the Priority List, or beginning a DoD collaboration are not questions for FDA. FDA will be unable to answer these questions.
The most efficient mechanisms for answering your questions are available to you on this page.

This Web site provides an introduction to the U.S. Army Medical Research and Development Command (USAMRDC) and contains official Government information. Its use is intended for members of the general public, news media and Army Medical Department beneficiaries. Please address questions or concerns about this website to the USAMRDC Public Affairs Office via
email
or by telephone at 301-619-2736.